Thyme Care
Thyme Care manages oncology care and takes financial risk on cancer spending for health plans.
On the record
Checkpoint: Robin Shah steps down as CEO to Executive Chairman; Brad Diephuis becomes CEO
The call
Thyme Care sits on real oncology risk contracts and payer relationships, but a founder handoff and new unproven business lines land at the same time policy dependency and thin margins stay in play.
Thyme Care is a licensed company that takes financial responsibility for cancer treatment costs across millions of patients, working between insurance companies and hospitals to control spending. It is hard to copy because it needs government licenses, trusted relationships with major payers like CVS and Humana, and access to real patient data that pure AI tools like Hippocratic AI cannot easily replicate. The biggest threat is not a specific competitor but the combination of three things happening at once: the company is switching CEOs in September 2026, launching unproven new business lines in drug affordability and clinical trials, and operating on thin profit margins where mistakes cost real money, and founder-to-operator handoffs in this type of business historically stumble most often.
Why
01
AI pressure: Hippocratic AI-style clinical agent platforms. AI agents could automate patient outreach and triage, but lack the licensure and risk contracts Thyme Care already holds with payers. Could AI do the core job? Unlikely.
02
Bigger players: CVS Health and Humana. Both are Thyme Care investors today, but either could choose to build oncology navigation in-house instead of paying Thyme Care. Could a giant copy it? Probably.
03
What protects it. Licensed risk-bearing contracts, direct relationships with 1,000+ oncologists, and claims data across 10.5 million lives that a new entrant cannot quickly copy.
What would change this call
CEO transition completes Sept 1, 2026 (Shah to Executive Chairman, Diephuis to CEO). Tests whether founder-to-operator handoff disrupts execution during new business-line launches.
CMS decisions on Enhancing Oncology Model or ACO REACH funding in 2026-2027. Shows whether Thyme Care's revenue base tied to government risk programs holds or shrinks.
Independent audit or GAAP disclosure of Thyme Care's claimed profitability. Confirms whether the profitability claim reflects real earnings or only contribution margin.
CMS decisions on Enhancing Oncology Model or ACO REACH funding in 2026-2027. Shows whether Thyme Care's revenue base tied to government risk programs holds or shrinks.
Independent audit or GAAP disclosure of Thyme Care's claimed profitability. Confirms whether the profitability claim reflects real earnings or only contribution margin.
Key numbers
- $6 billion in oncology spend managed
- 10.5 million covered lives across all 50 states
- $97M Series D, valuation over $1 billion
Named risks
- Dependence on CMS value-based programs like Enhancing Oncology Model and ACO REACH for Medicare-linked revenue.
- Profitability claim from Sept 2025 is company-stated and not independently audited.
- CEO transition effective Sept 1, 2026 coincides with launch of unproven new business lines in drug affordability and clinical trials.
- Multiple well-funded peers (Jasper Health, Reimagine Care, Solace) compete for the same value-based oncology niche.
- Healthcare sector-wide PHI data breach exposure, with 3,322 industry incidents recorded in 2025.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Jasper Health | contesting | Virtual supportive cancer care peer competing in same navigation niche, as of 2025-09-15 |
| Reimagine Care | contesting | Virtual oncology care competitor listed among Thyme Care's closest peers |
| Solace | contesting | Named alongside Thyme Care and Reimagine Care as a sector Leader as of 2026-06-08 |
| CVS Health | losing to | Chose to invest as Series D strategic backer (Sept 2025) rather than build in-house oncology navigation |
| Humana | losing to | Became Series D strategic investor Sept 2025 rather than competing directly |
| Optum | contesting | Has adjacent in-house Cancer Guidance Program capability that could compete if scaled |
Questions people ask
- Is Thyme Care profitable in 2026?
- Thyme Care says it reached profitability around its $97M Series D in September 2025, but this is a company claim, not an independently audited figure. By July 2026 it reported managing $6B in oncology spend across 10.5 million covered lives, though profitability details have not been externally verified.
- Who owns Thyme Care?
- Thyme Care is privately held, founded in 2020 by Robin Shah and Dr. Bobby Green. Backers include CVS Health Ventures, Humana, Morgan Health, a16z Bio+Health, Foresite Capital and Town Hall Ventures, with total funding of $275M and a valuation pushed above $1 billion after its September 25, 2025 Series D.
- Could AI replace Thyme Care?
- Unlikely to fully replace it. Thyme Care uses AI internally, like its AI Acuity Engine launched March 2026, for triage and documentation, but its moat rests on licensed clinical entities and two-sided financial risk contracts with payers, which a pure AI vendor cannot legally or structurally replicate.
- Is Thyme Care a good company to join in 2026?
- Headcount roughly quadrupled from about 120 in August 2023 to near 550 to 600 by mid-2026, but active hiring postings fell 42% in 2026 per Revelio Labs, and a CEO transition to Dr. Brad Diephuis takes effect September 1, 2026 alongside new, unproven business lines.
- Who is Thyme Care's biggest competitor?
- Peers in value-based oncology navigation include Jasper Health, Reimagine Care and Solace. Notably, national payers CVS Health and Humana chose to become strategic investors in Thyme Care's September 2025 Series D rather than build competing in-house programs.
- How many people work at Thyme Care?
- Estimates vary by source: Revelio Labs put headcount at about 599 as of March 2026, up from 141 in 2023, while Crustdata estimated about 547 employees as of July 2026, up roughly 27% year over year.
Timeline
- 2026-07-15Leadership change announced: Diephuis to CEO, Shah to Executive Chairman effective Sept 1, 2026; $6B managed spend, 10.5M lives reported
- 2026-05-19Named to CNBC's 2026 Disruptor 50 list
- 2026-04-13Named to Inc. 2026 fastest-growing list; reports 1,000 to 1,400 oncologists, 85,000 members
- 2026-03-31Ranked No. 20 on Inc.'s 2026 Southeast fastest-growing private companies list
- 2026-03-06Launched Integrated Social Support model powered by AI Acuity Engine, scaled to 40+ social workers
- 2025-10-30Appointed Ross Feinstein as Head of AI Platform
- 2025-09-25Closed $97M Series D; valuation pushed north of $1 billion; claimed profitability
- 2024-07Closed $95M Series C ($55M equity, $40M debt); total raised reaches $178M
- 2023-08Closed $60M Series B led by Town Hall Ventures
- 2021-10Closed $22M Series A led by Frist Cressey Ventures
Revision history
29 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Thyme Care lands $97M series D backed by CVS Health, Humana, Morgan Health & Memorial Hermann (2025-09-25)
- Dr. Brad Diephuis Named Chief Executive Officer... (2026-07-15)
- Inc. Names Thyme Care to Its 2026 List... (2026-04-13)
- Thyme Care - Headcount, Funding & Open Jobs (2026-07-17)
- Thyme Care Closes $95M Series C To Fuel Cancer Care Affordability
- Inc. Names Thyme Care to Its 2026 List of the Fastest-Growing Private Companies in the Southeast (2026-03-31)
- Thyme Care's AI-Driven Oncology Platform Lands Spot on 2026 CNBC Disruptor 50 List (2026-05-19)
- Thyme Care Number of Employees 2026 (2026-06-29)
- Scaling Our Team, the Thyme Care Way (2025-06-06)
- Thyme Care Strengthens Its Product Leadership... (2025-10-30)
- Thyme Care Launches Integrated Social Support (ISS) Model Powered by AI Acuity Engine (2026-03-06)
- Thyme Care - $22M Raised - Reviews & Alternatives (2026-07-15)